Cancer and neoplasms
Resection of the primary tumor improves the prognosis of gastrointestinal neuroendocrine neoplasms with liver metastases: mutual validation based on SEER database and institutional data
Nov
Pavel M, Oberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–60.
Google Scholar
Oberg KE. Gastrointestinal neuroendocrine tumors. Ann Oncol. 2010;21(Suppl 7):vii72–80.
Google Scholar
Eto K, Yoshida N, Iwagami S, Iwatsuki M, Baba H. Surgical treatment for gastrointestinal neuroendocrine tumors. Ann Gastroenterol Surg. 2020;4(6):652–9.
Google Scholar
Xu Z, Wang L, Dai S, Chen M, Li F, Sun J, Luo F. Epidemiologic trends of and factors associated with overall survival for patients with Gastroenteropancreatic neuroendocrine tumors in the United States. JAMA Netw Open. 2021;4(9):e2124750.
Google Scholar
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.
Google Scholar
Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am. 2011;40(1).
Riihimaki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer. 2016;139(12):2679–86.
Google Scholar
Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934–59.
Google Scholar
Goretzki PE, Mogl MT, Akca A, Pratschke J. Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract. Rev Endocr Metab Disord. 2018;19(2):169–78.
Google Scholar
Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197(1):29–37.
Google Scholar
Tierney JF, Chivukula SV, Wang X, Pappas SG, Schadde E, Hertl M, et al. Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors. Surgery. 2019;165(3):644–51.
Google Scholar
Bertani E, Zugni F, Radice D, Spada F, Bonomo G, Fumagalli Romario U, et al. Predicting resectability of primary tumor and mesenteric lymph-node masses in patients with small-intestine neuroendocrine tumors. Updat Surg. 2022;74(5):1697–704.
Google Scholar
Lewis A, Raoof M, Ituarte PHG, Williams J, Melstrom L, Li D, et al. Resection of the primary gastrointestinal neuroendocrine tumor improves survival with or without liver treatment. Ann Surg. 2019;270(6):1131–7.
Google Scholar
Zheng M, Li Y, Li T, Zhang L, Zhou L. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: a SEER-based analysis. Cancer Med. 2019;8(11):5128–36.
Google Scholar
Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, et al. ENETS consensus guidelines for high-grade Gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103(2):186–94.
Google Scholar
Felder S, Jann H, Arsenic R, Denecke T, Prasad V, Knappe-Drzikova B, et al. Gastric neuroendocrine neoplasias: manifestations and comparative outcomes. Endocr Relat Cancer. 2019;26(9):751–63.
Google Scholar
Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2021;19(7):839–68.
Google Scholar
Li Z, Ren H, Wang T, Zhang X, Zhao L, Sun C, et al. Resection of the primary tumor improves the survival of patients with stage IV gastric neuroendocrine carcinoma. Front Oncol. 2022;12:930491.
Google Scholar
Selberherr A, Freermann S, Koperek O, Niederle MB, Riss P, Scheuba C, Niederle B. Neuroendocrine liver metastasis from the small intestine: is surgery beneficial for survival? Orphanet J Rare Dis. 2021;16(1):30.
Google Scholar
Daskalakis K, Karakatsanis A, Hessman O, Stuart HC, Welin S, Tiensuu Janson E, et al. Association of a Prophylactic Surgical Approach to stage IV small intestinal neuroendocrine tumors with survival. JAMA Oncol. 2018;4(2):183–9.
Google Scholar
Ahmed A, Turner G, King B, Jones L, Culliford D, McCance D, et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer. 2009;16(3):885–94.
Google Scholar
Sorbye H, Grande E, Pavel M, Tesselaar M, Fazio N, Reed NS, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma. J Neuroendocrinol. 2023;35(3):e13249.
Google Scholar
Citterio D, Pusceddu S, Facciorusso A, Coppa J, Milione M, Buzzoni R, et al. Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver. Eur J Surg Oncol. 2017;43(2):380–7.
Google Scholar
Yoshida T, Hijioka S, Hosoda W, Ueno M, Furukawa M, Kobayashi N, et al. Surgery for pancreatic neuroendocrine tumor G3 and carcinoma G3 should be considered separately. Ann Surg Oncol. 2019;26(5):1385–93.
Google Scholar
Rossi RE, Corti F, Pusceddu S, Milione M, Coppa J, Masoni B, et al. Multidisciplinary approach to the diagnosis of occult primary neuroendocrine neoplasm: a clinical challenge. J Clin Med. 2023;12(17).
Gangi A, Manguso N, Gong J, Crystal JS, Paski SC, Hendifar AE, Tuli R. Midgut neuroendocrine tumors with liver-only metastases: benefit of primary tumor resection. Ann Surg Oncol. 2020;27(11):4525–32.
Google Scholar
Lin J, Zhao Y, Zhou Y, Tian Y, He Q, Lin J, et al. Comparison of survival and patterns of recurrence in gastric neuroendocrine carcinoma, mixed Adenoneuroendocrine carcinoma, and adenocarcinoma. JAMA Netw Open. 2021;4(7):e2114180.
Google Scholar
Kidd M, Modlin I, Öberg K. Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms. Nat Rev Clin Oncol. 2016;13(11):691–705.
Google Scholar
Mosquera C, Koutlas NJ, Fitzgerald TL. Localized high-grade gastroenteropancreatic neuroendocrine tumors: defining prognostic and therapeutic factors for a disease of increasing clinical significance. Eur J Surg Oncol. 2016;42(10):1471–7.
Google Scholar
Rinke A, Auernhammer CJ, Bodei L, Kidd M, Krug S, Lawlor R, et al. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? Gut. 2021;70(9):1768–81.
Google Scholar
Asa SL, Uccella S, Tischler A. The unique importance of differentiation and function in endocrine neoplasia. Endocr Pathol. 2023. https://doi.org/10.1007/s12022-023-09762-4.
Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115–54.
Google Scholar
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.
Google Scholar
Cope J, Srirajaskanthan R. Rectal neuroendocrine neoplasms: why is there a global variation? Curr Oncol Rep. 2022;24(3):257–63.
Google Scholar
Fraenkel M, Kim M, Faggiano A, de Herder WW, Valk GD. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 2014;21(3):R153-RR63.
Google Scholar
Le Treut YP, Grégoire E, Belghiti J, Boillot O, Soubrane O, Mantion G, et al. Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. Am J Transplant. 2008;8(6):1205–13.
Google Scholar
Dhupar R, de Vera ME, Marsh JW, Fontes PA, Steel JL, Zeh HJ, Gamblin TC. Simultaneous pancreatectomy and liver transplantation: a single-institution experience. HPB (Oxford). 2009;11(3):242–6.
Google Scholar
Chen Q, Li K, Rhodin KE, Bartholomew AJ, Lidsky ME, Wei Q, et al. Impact of primary tumor resection and metastasectomy among gastroentero-pancreatic neuroendocrine tumors with liver metastases only on survival. HPB (Oxford). 2023;S1365-182X(23):01941–X. https://doi.org/10.1016/j.hpb.2023.09.016.
Klöppel G, La Rosa S. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms. Virchows Arch. 2018;472(3):341–9.
Google Scholar
Boninsegna L, Panzuto F, Partelli S, Capelli P, Delle Fave G, Bettini R, et al. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer. 2012;48(11):1608–15.
Google Scholar
Lanari J, Hagness M, Sartori A, Rosso E, Gringeri E, Dueland S, et al. Liver transplantation versus liver resection for colorectal liver metastasis: a survival benefit analysis in patients stratified according to tumor burden score. Transpl Int. 2021;34(9):1722–32.
Google Scholar
Siriwardena AK, Mason JM, Mullamitha S, Hancock HC, Jegatheeswaran S. Management of colorectal cancer presenting with synchronous liver metastases. Nat Rev Clin Oncol. 2014;11(8):446–59.
Google Scholar
Chen J-N, Shoucair S, Wang Z, Habib JR, Zhao F-Q, Yu J, et al. Primary tumor resection for rectal Cancer with Unresectable liver metastases: a chance to cut is a chance for improved survival. Front Oncol. 2021;11:628715.
Google Scholar
Touloupas C, Faron M, Hadoux J, Deschamps F, Roux C, Ronot M, et al. Long term efficacy and assessment of tumor response of Transarterial chemoembolization in neuroendocrine liver metastases: a 15-year monocentric experience. Cancers (Basel). 2021;13(21).
Fiore F, Del Prete M, Franco R, Marotta V, Ramundo V, Marciello F, et al. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine. 2014;47(1):177–82.
Google Scholar
